Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA
Authors:
Open Access
- 26 July 2023
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Late Presentation of Carfilzomib Associated Thrombotic MicroangiopathyAmerican Journal of Medical Case Reports, 2019
- Síndrome hemolítico urémico atípico secundario al uso de carfilzomib tratado con eculizumabNefrología, 2019
- Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletionBlood Advances, 2018
- Diagnostic approach to microangiopathic hemolytic disordersInternational Journal of Laboratory Hematology, 2017
- Thrombotic microangiopathy during carfilzomib use: case series in SingaporeBlood Cancer Journal, 2016
- Proteasome inhibitor associated thrombotic microangiopathyAmerican Journal of Hematology, 2016
- Kidney Disease Caused by Dysregulation of the Complement Alternative PathwayJournal of the American Society of Nephrology, 2015
- Impairment of the Ubiquitin-Proteasome Pathway in RPE Alters the Expression of Inflammation Related Genes2014
- NoticeKidney International Supplements, 2012
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008